Danish drugmaker Lundbeck A/S (LUND: DC) says it has crowned six years of focused efforts on productivity improvements with a silver medallion in the prestigious Shingo competition. This is the first time a European company has been awarded the silver medallion.
The honor is given in recognition of Lundbeck's work to introduce new production principles that have led to significant improvements in business productivity. Lundbeck has succeeded in cutting the cost of internally produced products by roughly a quarter compared to 2006 levels.
The company believes it has beaten its peers and saved 2 billion Danish kroner ($341 million) since 2006 by means of in-house competitive improvements that have allowed it to end all outsourcing and to compete with Chinese producers, according to a Financial Times report.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze